Literature DB >> 30691963

Durable Clinical Response to Crizotinib in IRF2BP2-NTRK1 Non-small-cell Lung Cancer.

Buhai Wang1, Ye Gao2, Yuxiang Huang2, Qiuxiang Ou3, Tingting Fang2, Chunhui Tang2, Xue Wu3, Yang W Shao4.   

Abstract

Entities:  

Keywords:  Crizotinib; IRF2BP2; NSCLC; NTRK fusion; Pan-TRK inhibitor

Mesh：

Substances：

Year:  2018        PMID： 30691963     DOI： 10.1016/j.cllc.2018.12.017

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN： 1525-7304            Impact factor:   4.785


× No keyword cloud information.
  3 in total

1.  Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR-mutant NSCLC patient with acquired LMNA-NTRK1 fusion following osimertinib resistance.

Authors:  Jiao-Li Wang; Liu-Sheng Wang; Jun-Qi Zhu; Jie Ren; Di Wang; Man Luo
Journal:  Respirol Case Rep       Date:  2022-10-17

2.  High-throughput sequencing detection and ensartinib treatment of lung cancer harboring NTRK1 fusion.

Authors:  Zhengbo Song; Chunwei Xu; Xingxiang Pu; Youcai Zhu; Wenxian Wang; Xingliang Li; Yanqiu Gao; Wenliang Zhu; Yunwei He; Lin Wu; Li Mao; Li Chen; Ming Chen
Journal:  Cancer Commun (Lond)       Date:  2021-01-16

Review 3.  NTRK Fusion in Non-Small Cell Lung Cancer: Diagnosis, Therapy, and TRK Inhibitor Resistance.

Authors:  Fangfang Liu; Yuxuan Wei; Huan Zhang; Jizong Jiang; Peng Zhang; Qian Chu
Journal:  Front Oncol       Date:  2022-03-17       Impact factor: 6.244
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.